There are currently 34 active clinical trials seeking participants for Liver Cancer research studies. The states with the highest number of trials for Liver Cancer participants are California, England, Illinois and New York.
National Liver Cancer Screening Trial
NCT06084234
Recruiting
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), an... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/27/2024
Locations: University of Southern California, Los Angeles, California +9 locations
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Register for Updates
Biobank for Cholestatic Liver Diseases.
NCT03445585
Recruiting
This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/14/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Register for Updates
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
NCT04634357
Recruiting
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
03/05/2024
Locations: UCSF Benioff Children's Hospitals, San Francisco, California +1 locations
Conditions: Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS
Register for Updates
Registry to Collect Health Information Related to Fibrolamellar Cancer
NCT04874519
Recruiting
The purpose of this study is to collect information about people with fibrolamellar cancer (FLC). This study is a registry of people with FLC around the world. This study will involve collecting information about participants, their medical history and the regular medical care they receive for FLC. The study will not provide treatment for your cancer.
Gender:
All
Ages:
13 years and above
Trial Updated:
03/04/2024
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Fibrolamellar Cancer, FLC, Liver Cancer
Register for Updates
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
All
Ages:
Between 19 years and 110 years
Trial Updated:
02/29/2024
Locations: Penrose Cancer Center, Colorado Springs, Colorado +83 locations
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
NCT00373347
Recruiting
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Liver Cancer
Register for Updates
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies
NCT02853500
Recruiting
This research study is studying the TriNav ("TriSalus") for increasing delivery of chemotherapeutic agents delivered trans-arterially to intermediate stage Hepatocellular Carcinoma ("HCC") (Barcelona Clinic Liver Cancer (BCLC) class B; locally advanced, liver restricted disease patients. The names of the study interventions involved in this study are: -Trans-arterial chemoembolization ("TACE") with or without the utilization of Surefire
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Liver Cancer
Register for Updates
Domvanalimab and Zimberelimab in Advanced Liver Cancers
NCT05724563
Recruiting
The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is: If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary cancers that have failed prior treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
Register for Updates
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT05146297
Recruiting
This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative research is captured by its acronym, DISRUPT: Diversity & IncluSion in Research Underpinning Prevention & Therapy Trials. To disrupt the norms that maintain heightened risk and poorer outcomes experience... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
01/02/2024
Locations: Albert Einstein College of Medicine, Bronx, New York +2 locations
Conditions: Breast Cancer, Liver Cancer, Prostate Cancer
Register for Updates
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
NCT05727787
Recruiting
This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique. Based on trials using this type of radiation in other cancers demonstrating low toxicity rates even with very high radiation doses and high efficacy, it is likely that vGRID therapy in this trial will be well tolerated and allow dose escalation beyond currently common doses for liver tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Liver Cancer
Register for Updates
A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene
NCT05497453
Recruiting
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma (HCC) and other solid tumor types known for association with the MYC oncogene. The study consists of Part 1 (OTX-2002 monotherapy) and Part 2 (OTX-2002 combined with standard of care in hepatocellular carcinoma). Part 1 consists of escalati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: City of Hope, Duarte, California +15 locations
Conditions: Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Hepatocellular Cancer, Liver Cancer, Liver, Cancer of, Non-Resectable
Register for Updates
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
NCT05517811
Recruiting
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with vi... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
12/15/2023
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma, Control, Pancreas Cancer, Biliary Cancer
Register for Updates